A citation-based method for searching scientific literature

Mu-Yang Huang, Xiao-Ming Jiang, Bing-Lin Wang, Yang Sun, Jin-Jian Lu. Pharmacol Ther 2021
Times Cited: 10







List of co-cited articles
20 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.
Hossein Borghaei, Luis Paz-Ares, Leora Horn, David R Spigel, Martin Steins, Neal E Ready, Laura Q Chow, Everett E Vokes, Enriqueta Felip, Esther Holgado,[...]. N Engl J Med 2015
40

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Julie Brahmer, Karen L Reckamp, Paul Baas, Lucio Crinò, Wilfried E E Eberhardt, Elena Poddubskaya, Scott Antonia, Adam Pluzanski, Everett E Vokes, Esther Holgado,[...]. N Engl J Med 2015
40

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe,[...]. N Engl J Med 2016
30

Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlook.
Lena Horvath, Bernard Thienpont, Liyun Zhao, Dominik Wolf, Andreas Pircher. Mol Cancer 2020
24
20

Lung cancer: current therapies and new targeted treatments.
Fred R Hirsch, Giorgio V Scagliotti, James L Mulshine, Regina Kwon, Walter J Curran, Yi-Long Wu, Luis Paz-Ares. Lancet 2017
20


Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell, Enric Carcereny, Radj Gervais, Alain Vergnenegre, Bartomeu Massuti, Enriqueta Felip, Ramon Palmero, Ramon Garcia-Gomez, Cinta Pallares, Jose Miguel Sanchez,[...]. Lancet Oncol 2012
20

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
20

Efficacy and Safety of Sintilimab Plus Pemetrexed and Platinum as First-Line Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC: a Randomized, Double-Blind, Phase 3 Study (Oncology pRogram by InnovENT anti-PD-1-11).
Yunpeng Yang, Zhehai Wang, Jian Fang, Qitao Yu, Baohui Han, Shundong Cang, Gongyan Chen, Xiaodong Mei, Zhixiong Yang, Rui Ma,[...]. J Thorac Oncol 2020
50
20


Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC.
Roy S Herbst, Giuseppe Giaccone, Filippo de Marinis, Niels Reinmuth, Alain Vergnenegre, Carlos H Barrios, Masahiro Morise, Enriqueta Felip, Zoran Andric, Sarayut Geater,[...]. N Engl J Med 2020
188
20

Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial.
Roy S Herbst, Paul Baas, Dong-Wan Kim, Enriqueta Felip, José L Pérez-Gracia, Ji-Youn Han, Julian Molina, Joo-Hang Kim, Catherine Dubos Arvis, Myung-Ju Ahn,[...]. Lancet 2016
20

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
20

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.
Achim Rittmeyer, Fabrice Barlesi, Daniel Waterkamp, Keunchil Park, Fortunato Ciardiello, Joachim von Pawel, Shirish M Gadgeel, Toyoaki Hida, Dariusz M Kowalski, Manuel Cobo Dols,[...]. Lancet 2017
20

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.
Louis Fehrenbacher, Alexander Spira, Marcus Ballinger, Marcin Kowanetz, Johan Vansteenkiste, Julien Mazieres, Keunchil Park, David Smith, Angel Artal-Cortes, Conrad Lewanski,[...]. Lancet 2016
20

Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Takaaki Tokito, Koichi Azuma, Akihiko Kawahara, Hidenobu Ishii, Kazuhiko Yamada, Norikazu Matsuo, Takashi Kinoshita, Naohisa Mizukami, Hirofumi Ono, Masayoshi Kage,[...]. Eur J Cancer 2016
120
20

Maftools: efficient and comprehensive analysis of somatic variants in cancer.
Anand Mayakonda, De-Chen Lin, Yassen Assenov, Christoph Plass, H Phillip Koeffler. Genome Res 2018
611
20

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Naiyer A Rizvi, Julien Mazières, David Planchard, Thomas E Stinchcombe, Grace K Dy, Scott J Antonia, Leora Horn, Hervé Lena, Elisa Minenza, Bertrand Mennecier,[...]. Lancet Oncol 2015
963
20

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
278
20

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
Caicun Zhou, Yi-Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren,[...]. Lancet Oncol 2011
20


Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations.
Judith A Seidel, Atsushi Otsuka, Kenji Kabashima. Front Oncol 2018
412
10

Tumor immunoevasion via acidosis-dependent induction of regulatory tumor-associated macrophages.
Toszka Bohn, Steffen Rapp, Natascha Luther, Matthias Klein, Till-Julius Bruehl, Nobuhiko Kojima, Pamela Aranda Lopez, Jennifer Hahlbrock, Sabine Muth, Shogo Endo,[...]. Nat Immunol 2018
113
10

Molecular and clinical characterization of CD163 expression via large-scale analysis in glioma.
Shasha Liu, Chaoqi Zhang, Nomathamsanqa Resegofetse Maimela, Li Yang, Zhen Zhang, Yu Ping, Lan Huang, Yi Zhang. Oncoimmunology 2019
24
10

The gift of Gab.
Yan Liu, Larry R Rohrschneider. FEBS Lett 2002
161
10

Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes.
Izidore S Lossos, Debra K Czerwinski, Ash A Alizadeh, Mark A Wechser, Rob Tibshirani, David Botstein, Ronald Levy. N Engl J Med 2004
665
10

Engineering Macrophages for Cancer Immunotherapy and Drug Delivery.
Yuqiong Xia, Lang Rao, Huimin Yao, Zhongliang Wang, Pengbo Ning, Xiaoyuan Chen. Adv Mater 2020
59
10

Macrophages promote endothelial-to-mesenchymal transition via MT1-MMP/TGFβ1 after myocardial infarction.
Laura Alonso-Herranz, Álvaro Sahún-Español, Ana Paredes, Pilar Gonzalo, Polyxeni Gkontra, Vanessa Núñez, Cristina Clemente, Marta Cedenilla, María Villalba-Orero, Javier Inserte,[...]. Elife 2020
7
14

Dual Roles for Ikaros in Regulation of Macrophage Chromatin State and Inflammatory Gene Expression.
Kyu-Seon Oh, Rachel A Gottschalk, Nicolas W Lounsbury, Jing Sun, Michael G Dorrington, Songjoon Baek, Guangping Sun, Ze Wang, Kathleen S Krauss, Joshua D Milner,[...]. J Immunol 2018
15
10



Generalized LASSO with under-determined regularization matrices.
Junbo Duan, Charles Soussen, David Brie, Jérôme Idier, Mingxi Wan, Yu-Ping Wang. Signal Processing 2016
10
10


Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors.
Qingyang Lei, Dan Wang, Kai Sun, Liping Wang, Yi Zhang. Front Cell Dev Biol 2020
26
10

A five-gene signature and clinical outcome in non-small-cell lung cancer.
Hsuan-Yu Chen, Sung-Liang Yu, Chun-Houh Chen, Gee-Chen Chang, Chih-Yi Chen, Ang Yuan, Chiou-Ling Cheng, Chien-Hsun Wang, Harn-Jing Terng, Shu-Fang Kao,[...]. N Engl J Med 2007
663
10


USP7 targeting modulates anti-tumor immune response by reprogramming Tumor-associated Macrophages in Lung Cancer.
Xiaomeng Dai, Lisen Lu, Suke Deng, Jingshu Meng, Chao Wan, Jing Huang, Yajie Sun, Yan Hu, Bian Wu, Gang Wu,[...]. Theranostics 2020
11
10


Prognostic impact of tumor-associated macrophage infiltration in esophageal cancer: a meta-analysis.
Jiangfen Li, Yufang Xie, Xueli Wang, Feng Li, Shugang Li, Man Li, Hao Peng, Lan Yang, Chunxia Liu, Lijuan Pang,[...]. Future Oncol 2019
22
10

Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape.
Takuro Noguchi, Jeffrey P Ward, Matthew M Gubin, Cora D Arthur, Sang Hun Lee, Jasreet Hundal, Mark J Selby, Robert F Graziano, Elaine R Mardis, Alan J Korman,[...]. Cancer Immunol Res 2017
132
10

Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies.
Elisabeth Pérez-Ruiz, Ignacio Melero, Joanna Kopecka, Ana Bela Sarmento-Ribeiro, Marilina García-Aranda, Javier De Las Rivas. Drug Resist Updat 2020
32
10

Gab3 is required for human colorectal cancer cell proliferation.
Shihao Xiang, Na Wang, Pingping Hui, Jiali Ma. Biochem Biophys Res Commun 2017
7
14

Transcriptional Regulation of Genes by Ikaros Tumor Suppressor in Acute Lymphoblastic Leukemia.
Pavan Kumar Dhanyamraju, Soumya Iyer, Gayle Smink, Yevgeniya Bamme, Preeti Bhadauria, Jonathon L Payne, Elanora Dovat, Morgann Klink, Yali Ding. Int J Mol Sci 2020
3
33

The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia.
Zi-Jun Xu, Yu Gu, Cui-Zhu Wang, Ye Jin, Xiang-Mei Wen, Ji-Chun Ma, Li-Juan Tang, Zhen-Wei Mao, Jun Qian, Jiang Lin. Oncoimmunology 2019
25
10

Gab3 is required for IL-2- and IL-15-induced NK cell expansion and limits trophoblast invasion during pregnancy.
Anna Sliz, Kathryn C S Locker, Kristin Lampe, Alzbeta Godarova, David R Plas, Edith M Janssen, Helen Jones, Andrew B Herr, Kasper Hoebe. Sci Immunol 2019
13
10


A ceRNA network and a potential regulatory axis in gastric cancer with different degrees of immune cell infiltration.
Kai Zhang, Lei Zhang, Yang Mi, YouCai Tang, FeiFei Ren, Bin Liu, Yi Zhang, PengYuan Zheng. Cancer Sci 2020
10
10

Cancer statistics, 2020.
Rebecca L Siegel, Kimberly D Miller, Ahmedin Jemal. CA Cancer J Clin 2020
10

Targeting macrophages: therapeutic approaches in cancer.
Luca Cassetta, Jeffrey W Pollard. Nat Rev Drug Discov 2018
460
10

KEGG for representation and analysis of molecular networks involving diseases and drugs.
Minoru Kanehisa, Susumu Goto, Miho Furumichi, Mao Tanabe, Mika Hirakawa. Nucleic Acids Res 2010
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.